Adult SSRI Use And Suicidality To Get FDA Advisory Committee Review, J&J Says
This article was originally published in The Pink Sheet Daily
Executive Summary
A committee will meet within the next few months to review selective serotonin reuptake inhibitors and suicidality in adults, J&J Senior VP Waldstreicher says. The company’s NDA for the SSRI dapoxetine is pending; J&J is seeking to differentiate the premature ejaculation agent from the rest of the class.